



BRCA-Associated Breast Cancer

Guest Editors:

Dr. Matilde Pensabene

Department of Breast and Thoracic Oncology, Division of Breast Medical Oncology, National Cancer Institute, IRCCS “Fondazione G. Pascale”, 80131 Naples, Italy

Dr. Carmine De Angelis

Medical Oncology, Department of Clinical Medicine and Surgery, University Federico II, 80131 Naples, Italy

Prof. Dr. Matteo Lambertini

IRCCS Ospedale Policlinico San Martino, University of Genova, Genoa, Italy

Deadline for manuscript submissions:

closed (15 May 2024)

Message from the Guest Editors

About 5-10% of breast cancers (BCs) are related to BRCA1 or BRCA2 pathogenetic variants. In recent years, an increasing number of advancements have been made concerning molecular diagnosis, genetic testing, the management of early or metastatic carcinoma, the management of long-survival patients for their risk of second primary tumors, surgical procedures, and clinical follow-up. Few data are available concerning the specific site of pathogenetic variants and the associated cancer spectrum. Variants of unknown significance foresee active research. Currently, fertility and fertility preservation in females with BRCA-associated BC are highly relevant topics in this oncological field.

This Special Issue, entitled “BRCA-associated breast cancer”, is devoted to reporting original research, review, and real-world experiences in this field, examining these topics from different perspectives, i.e., oncological, radiological, surgical, and psychological perspectives. Systematic reviews are also welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)